# Asia Pacific Insomnia Market

> Asia Pacific Insomnia Market Research Report, By Types Of Therapy (Pharmacological Therapy And Non-Pharmacological Therapy), By Drug Formulation (Capsules, Tablet And Others), By Type Of Diseases (Poor Quality Of Sleep, Sleep Maintenance And Other) - Forecast Till 2035

- **CAGR:** 8.12%
- **2023:** $ 0.14 Billion
- **2024:** $ 0.18 Billion
- **2032:** $ 0.2 Billion
- **Key Players:** Key players include Takeda Pharmaceutical Company, Pfizer, Inc., Eisai, Co., Merck & Co Inc, Sanofi, and GlaxoSmithKline Plc.

**Report ID:** MRFR/Pharma/0176-HCR · **Pages:** 50 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/asia-pacific-insomnia-market-619

---

## Market Summary

As per Market Research Future Analysis, the Asia Pacific Insomnia Market was valued at USD 0.14 Billion in 2023 and is projected to grow to USD 0.20 Billion by 2032, with a CAGR of 8.12% from 2024 to 2032. Insomnia, the most prevalent sleep disorder, affects a significant portion of the population, particularly women and younger individuals. Factors such as increased alcohol, caffeine, and tobacco consumption, along with psychological and behavioral issues, are driving the rise in insomnia cases. The market is further supported by technological advancements and rising healthcare expenditures. However, a lack of education and awareness may hinder growth.

## Regional Market Share Analysis

**Regional Analysis**

On regional basis, Japan accounts the largest share in the Asia Pacific insomnia market. 1 in every 5 people in japan is suffering from acute or chronic symptoms of insomnia. In Japan insomnia is the major problem than anxiety and depression. India and China are also contribute major share in the market. Approximately 5% of total India’s population is suffering from insomnia. This increasing number of people suffering from insomnia is the major driving factor for the market in Asia Pacific region.

## Competitive Benchmarking

**Key Players for Asia Pacific Insomnia market**
Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan),  Merck & Co Inc (US), Sanofi (France),  GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK).**Segmentation**Asia Pacific [insomnia](https://www.marketresearchfuture.com/reports/insomnia-market-545) market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioural therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.

## Report Scope

| Attribute/Metric | Details |
| --- | --- |
| Market Size | USD 0.20 Billion by 2032 |
| CAGR | 8.12% (2024-2032) |
| Base Year |   2023 |
| Forecast Period |   2024-2032 |
| Historical Data |   2021 |
| Forecast Units |   Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, end user, Region |
| Geographies Covered | Asia Pacific |
| Key Vendors | Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan),  Merck & Co Inc (US), Sanofi (France),  GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK) |

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/asia-pacific-insomnia-market-619*